Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib

Journal of Oral Pathology and Medicine

Volumn 33, Issue 10, 2004, Pages 614-621

  Nishimura, Norihiko ^a   Urade, Masahiro ^a   Hashitani, Susumu ^a   Noguchi, Kazuma ^a   Manno, Yukiyo ^a   Takaoka, Kazuki ^a   Sakurai, Kazunari ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Celecoxib; Chemoprevention; Cyclooxygenase 2; DMBA; Hamster cheek pouch carcinogenesis

Indexed keywords

ACETONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYLBENZ[A]ANTHRACENE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CHEEK POUCH; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHEEK; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; ISOENZYMES; MALE; MESOCRICETUS; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 7944222372     PISSN: 09042512     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2004.00254.x     Document Type: Article

References (49)

1. Vane J. Towards a better aspirin. Nature 1994; 367: 215-6.
2. Dewitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988; 85: 1412-6.
3. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-8.
4. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89: 4888-92.
5. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and 2 expression in rheumatoid synovial tissues: effect of interleukin-1 β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101.
6. Thun MJ. NSAID use and decreased risk of gastrointestinal cancer. Gastroenterol Clin North Am 1996; 25: 333-48.
7. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6.
8. Greenberg ER, Baron JA, Freeman DHJ, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin user. J Natl Cancer Inst 1993; 85: 912-6.
9. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
10. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
11. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
12. Parrett ML, Harris R, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 503-7.
13. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998; 58: 4997-5001.
14. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
15. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-90.
16. Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 expression is overexpressed in human cervical cancer. Clin Cancer Res 2001; 7: 429-34.
17. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647-50.
18. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-96.
19. Leong J, Hughes-Fulfold M, Rakhlin N, Habib A, Maclouf J, Goldyne ME. Cyclooxygenase-2 in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996; 224: 79-87.
20. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59: 991-4.
21. Shiotani S, Denda A, Yamamoto K, et al. Increased expression of cyclooxygenase-2 protein in 4-Nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 2001; 61: 1451-6.
22. Urade M, Uematsu T, Mima T, Ogura T, Matsuya T. Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene. J Oral Pathol Med 1992; 21: 109-12.
23. Hsu SM, Raine L, Franger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
24. Ovejera AA, Houchens DP, Baker AD. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci 1978; 8: 50-6.
25. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
26. Thun MH, Namboordiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and reduced risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
27. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial polyposis. Cancer Res 1996; 56: 2556-60.
28. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7.
29. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
30. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-9.
31. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-23.
32. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
33. DuBois RN, Tsujii M, Bishop P, Awad JA, Makita K, Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994; 266: G822-7.
34. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
35. Honn KV, Bockmann RS, Marnett LJ. Prostaglandins and cancer: a review of tumour initiation through tumour metastasis. Prostaglandins 1981; 21: 833-64.
36. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-8.
37. Hashitani S, Urade M, Nishimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 2003; 23: 665-72.
38. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
39. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
40. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-11.
41. Lanza FL, Rack MF, Callison DA, et al. A pilot endoscopie study of the gastroduodenal effects of SC-58635, a novel COX-2 selective inhibitor. Gastroenterology 1997; 112: A194.
42. Kazanov D, Dvory-Sobol H, Pick M, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res 2004; 10: 267-71.
43. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64: 2030-8.
44. Masterrer JL, Leahy KM, Koki AT, Zweifel BS. Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-11.
45. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, Damato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-32.
46. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-72.
47. Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti-inflammatory efficacy at high doses by activation of NF-κB. FASEB J 2001; 15: 1622-4.
48. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21 waf1/cip1 and p27 kip1 and cell cycle arrest. Cancer Res 2004; 64: 1369-76.
49. Kulp, SK, Yang YT, Hung CC, et al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64: 1444-51.